Literature DB >> 23884647

Clinical and prothrombotic profile of hepatic vein outflow tract obstruction.

Seema Alam1, Rajeev Khanna, Amar Mukund.   

Abstract

OBJECTIVE: To study the clinical as well as prothrombotic profile and outcome of hepatic venous outflow tract obstruction in children.
METHODS: This is a prospective study of a cohort of hepatic venous outflow tract obstruction (HVOTO) pediatric cases. All children and adolescents presenting with acute or chronic liver disease were screened for HVOTO with ultrasound and Doppler imaging and confirmed by multidetector computerised tomography (MDCT) with contrast enhancement.
RESULTS: Of the 162 cases of chronic liver disease, 13 (7.4 %) were diagnosed to have HVOTO. Ascites and edema over the feet were the most prominent features. Anabolic steroids and herbal drugs were being taken by one case each. Six cases were diagnosed on Doppler and for rest 7 cases conclusive diagnosis was made on multidetector computerised tomography. Five out of 13 cases were heterogenous (CT) for mutation of the gene encoding methylene tetrahydrofolate reductase (MTHFR) and one case of these was also heterogenous for Factor Leiden V. One case was known celiac and developed HVOTO and was also found to be having hepatocellular carcinoma. Other causes were drug induced, pressure on inferior vena cava (IVC) and inferior vena cava (IVC) web. Thus the authors could find a prothrombotic cause for 10 out of 13 (76.9 %) cases. Three cases did not need any intervention. In one patient with infective thrombus of the IVC intervention was not planned. Six underwent angioplasty and 3 underwent transjugular intrahepatic portosystemic shunt. All were asymptomatic with improving growth parameters at follow up.
CONCLUSIONS: Ascites, pedal edema, prominent abdominal veins and hepatomegaly should raise the suspicion of HVOTO in childhood liver disease. Majority of the cases would be harbouring a prothrombotic cause. MTHFR mutation was the commonest cause of HVOTO in the present study. Angioplasty and/or transjugular intrahepatic portosystemic shunt (TIPSS) can successfully treat HVOTO.

Entities:  

Mesh:

Year:  2013        PMID: 23884647     DOI: 10.1007/s12098-013-1131-7

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  19 in total

1.  Duplex Doppler sonography in patients with Budd-Chiari syndrome.

Authors:  Y Chawla; S Kumar; R K Dhiman; S Suri; J B Dilawari
Journal:  J Gastroenterol Hepatol       Date:  1999-09       Impact factor: 4.029

Review 2.  Budd-Chiari syndrome: a review by an expert panel.

Authors:  Harry L A Janssen; Juan-Carlos Garcia-Pagan; Elwyn Elias; Gilles Mentha; Antoine Hadengue; Dominique-Charles Valla
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

3.  Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension.

Authors:  Roberto de Franchis
Journal:  J Hepatol       Date:  2005-07       Impact factor: 25.083

4.  Clinicopathological forms and prognostic index in Budd-Chiari syndrome.

Authors:  Philippe Langlet; Sylvie Escolano; Dominique Valla; Delphine Coste-Zeitoun; Cecile Denie; Alain Mallet; Victor-Georges Levy; Dominique Franco; Jean-Pierre Vinel; Jacques Belghiti; Didier Lebrec; Jean-Marie Hay; Guy Zeitoun
Journal:  J Hepatol       Date:  2003-10       Impact factor: 25.083

5.  Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study.

Authors:  Mohammad Sakr; Eman Barakat; Sara Abdelhakam; Hany Dabbous; Said Yousuf; Mohamed Shaker; Ahmed Eldorry
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

6.  Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal.

Authors:  S M Shrestha; K Okuda; T Uchida; K G Maharjan; S Shrestha; B L Joshi; S Larsson; Y Vaidya
Journal:  J Gastroenterol Hepatol       Date:  1996-02       Impact factor: 4.029

7.  Association of Budd-Chiari syndrome and celiac disease.

Authors:  N Afredj; S Metatla; S A Faraoun; A Nani; N Guessab; M Benhalima; S E Bendib; N Debzi; K Layaida; L Gamar; N Baiod; M Balamane; N Kaddache; N Bounab; L Kecili; T Boucekkine
Journal:  Gastroenterol Clin Biol       Date:  2010-10-08

Review 8.  Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism.

Authors:  Joel G Ray
Journal:  Curr Opin Pulm Med       Date:  2008-09       Impact factor: 3.155

9.  Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd-Chiari syndrome.

Authors:  J Ludwig; E Hashimoto; D B McGill; J A van Heerden
Journal:  Mayo Clin Proc       Date:  1990-01       Impact factor: 7.616

Review 10.  Primary Budd-Chiari syndrome.

Authors:  Dominique-Charles Valla
Journal:  J Hepatol       Date:  2008-10-26       Impact factor: 25.083

View more
  4 in total

1.  Infantile Budd Chiari and response to balloon dilatation.

Authors:  Ira Shah; Amit Dey; Sushmita Bhatnagar; Gireesh Warawdekar
Journal:  Indian J Pediatr       Date:  2014-06-10       Impact factor: 1.967

Review 2.  Prothrombin gene mutation in Budd-Chiari syndrome-The first case report from India.

Authors:  Abhinav Jain; Akash Shukla
Journal:  Indian J Gastroenterol       Date:  2018-04-04

3.  Budd-Chiari syndrome has different presentations and disease severity during adolescence.

Authors:  Akash Shukla; Pratin Bhatt; Deepak Kumar Gupta; Tejas Modi; Jatin Patel; Amit Gupte; Megha Meshram; Shobna Bhatia
Journal:  Hepatol Int       Date:  2018-07-03       Impact factor: 6.047

4.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.